



**ASX Announcement**  
**24 November 2022**

## **OPTISCAN CHAIRMAN'S AGM ADDRESS**

Optiscan Imaging Limited (ASX: OIL) ('the Company' or 'Optiscan') provides the following Chairman's address which will be made to the Annual General Meeting of shareholders today.

The past year has seen a number of changes to the Company with the appointment of Professor Camile Farah as Managing Director in December 2021, and the appointment of additional executive positions to help drive the Company's growth and objectives.

Over the past year the Company successfully lodged its FDA 510(k) pre-market notification application for the InVivage® device intended for oral tissue imaging. This was a key milestone for the Company and we look forward to finalising regulatory approval in due course. This will enable the Company to continue to commercialise its InVivage® device.

The Company and its newly appointed executives continue to market the Company and its technology. As discussed in the Managing Director's report, we have engaged with a number of medical institutions and have raised awareness at a number of international medical conferences and trade exhibitions.

We have also increased our manufacturing capabilities as we shape the Company for the future.

The Company is well positioned to be able to capitalise on its future objectives with the increase in these key appointments and increase in manufacturing capabilities.

On behalf of the Board, I would like to thank our shareholders for their continued and much valued support over the past year.

--ends--

**For investor queries, please contact:**

Prof Camile Farah  
CEO & Managing Director – Optiscan Imaging Ltd  
E: [cfarah@optiscan.com](mailto:cfarah@optiscan.com)

For more information about our products, visit [www.optiscan.com](http://www.optiscan.com)

### **About Optiscan**

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the sub-cellular level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

**Phone** (61 3) 9538 3333

**Website** [www.OptiScan.com](http://www.OptiScan.com)

16 Miles St, Mulgrave VIC 3170

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

## **Disclaimer**

*All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of OptiScan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of OptiScan that could cause actual results to differ from the results expressed or anticipated in these statements.*